Capmatinib resistance management

Capmatinib (Capmatinib) is a drug used to treat tumors related to MET exon 14 skipping mutations, but in some cases, patients may develop drug resistance. When a patient develops drug resistance, doctors need to deal with and adjust the treatment plan according to the specific situation.

1. Gene mutation analysis: When a patient develops drug resistance, gene mutation analysis must first be performed. This analysis can help determine whether there are new mutations or variants that render capmatinib ineffective on tumor cells. By analyzing genetic mutations, doctors can more accurately understand the patient's drug resistance mechanism, thereby providing guidance for the selection of subsequent treatment options.

2. Substitution of therapeutic drugs: Based on the results of gene mutation analysis, doctors can consider using other targeted therapeutic drugs to replace capmatinib. At present, a variety of targeted therapeutic drugs targeting MET mutations have been developed and applied, such as certain third-generation MET inhibitors. Doctors will choose alternative drugs suitable for patients based on individual treatment needs.

3. Combination therapy: Another way to deal with drug resistance is to use combination therapy. That is, capmatinib will be used in combination with other targeted drugs or chemotherapy drugs to enhance the efficacy and delay the occurrence of drug resistance. Combination therapy can act on tumor cells through different pathways, reduce the risk of drug resistance, and potentially provide better therapeutic effects.

For the treatment of capmatinib resistance, doctors should develop individualized treatment plans based on the patient's specific conditions. The selection of treatment options should be based on genetic mutation analysis, clinical trial results, and the latest research advances. Patients need to communicate closely with their doctors during the treatment process and follow the doctor's instructions for treatment and follow-up.